Interestingly there was no mention of Grifol's Xembify which could offset any softness in new CSL prescriptions. In the razor/razorblade model, there are higher margins on the razorblades(tubes and needles). So earnings could be somewhat cushioned?
All of these possible some day but no time frame has been offered.